Kitov Pharmaceuticals Says on July 6 Named Gil Ben-Menachem to Fill Vacancy on Board

 Kitov Pharmaceuticals Holdings Ltd. KTOV is announcing that on July 6, 2017 the Board of Directors (the “Board”) of the Company determined to fill a vacancy on the Board, and to appoint Gil Ben-Menachem, Ph.D., MBA to serve as a director of the Company, effective immediately.

 

Dr. Ben-Menachem has served as the Company’s vice president of business development since January 2016, as a member of the Board’s Science and Technology Committee since August 2016, and as a director at TyrNovo Ltd., the Company’s majority owned subsidiary, since February 2017. He has over 15 years of experience in the pharmaceutical, biotechnology, and venture capital industries. Prior to joining the Company, from 2013 he was head of innovative products at Dexcel Pharma, a large privately held Israeli pharmaceutical company. From 2012 to 2013, Dr. Ben-Menachem served as chief executive officer of OphthaliX, a company that developed drugs in the ophthalmology space. From 2008 to 2012 he served as director of business development at Teva Pharmaceutical Industries Ltd. TEVA, where he was responsible for business development efforts in connection with partnering and acquisition deals for late stage innovative drug candidates. Between 2005 and 2008 he served as director of business development at Paramount Biosciences, a New York based merchant bank and biotechnology venture capital firm. Dr. Ben-Menachem received his Ph.D. from the Hebrew University, and MBA from the University of Maryland. He concluded his postdoctoral training in immunology and microbiology at the National Institutes of Health (NIH), the U.S. Department of Health and Human Services’ medical research agency.